Literature DB >> 8747629

Meperidine: therapeutic use and toxicity.

R F Clark1, E M Wei, P O Anderson.   

Abstract

Meperidine is a synthetic opioid analgesic frequently prescribed in the emergency department. Meperidine is most often administered intramuscularly or intravenously, due to its poor oral bioavailability, and is metabolized extensively by the liver. Analgesic effects usually last 3-4 hours with parenteral administration, and some adverse effects such as nausea may be reduced when meperidine is combined with antiemetic or antihistaminic medications. Although meperidine is often a preferred analgesic by both patients and physicians in the treatment of disorders such as migraine headaches, its analgesic efficacy has rarely proven superior to alternative parenteral pain medications in controlled trials. In addition, meperidine can precipitate monoamine oxidase inhibitor reactions, and during metabolism it is demethylated to normeperidine, a compound with significant central nervous system (CNS) toxicity. Meperidine should be considered a second line agent in the treatment of pain when opioid analgesics are required.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8747629     DOI: 10.1016/0736-4679(95)02002-0

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  10 in total

1.  Meperidine restriction in a pediatric hospital.

Authors:  Kim W Benner; Spencer H Durham
Journal:  J Pediatr Pharmacol Ther       Date:  2011-07

2.  [The PRISCUS list in clinical routine. Practicability and comparison to international PIM lists].

Authors:  S Siebert; B Elkeles; G Hempel; J Kruse; M Smollich
Journal:  Z Gerontol Geriatr       Date:  2013-01       Impact factor: 1.281

3.  The effects of tramadol on static and dynamic pupillometry in healthy subjects--the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status.

Authors:  Frank Fliegert; Burkhard Kurth; Karin Göhler
Journal:  Eur J Clin Pharmacol       Date:  2005-05-20       Impact factor: 2.953

Review 4.  Pain Management in Pediatric Chronic Kidney Disease.

Authors:  Amanda Reis; Caitlyn Luecke; Thomas Keefe Davis; Aadil Kakajiwala
Journal:  J Pediatr Pharmacol Ther       Date:  2018 May-Jun

Review 5.  Management of opioid analgesic overdose.

Authors:  Edward W Boyer
Journal:  N Engl J Med       Date:  2012-07-12       Impact factor: 91.245

6.  Impact of cytochrome P450 variation on meperidine N-demethylation to the neurotoxic metabolite normeperidine.

Authors:  Jessica L Murray; Susan L Mercer; Klarissa D Jackson
Journal:  Xenobiotica       Date:  2019-04-24       Impact factor: 1.908

7.  Chronopharmacodynamics and chronopharmacokinetics of pethidine in mice.

Authors:  Chengliang Zhang; Zaoqin Yu; Xiping Li; Yanjiao Xu; Dong Liu
Journal:  PLoS One       Date:  2014-07-15       Impact factor: 3.240

8.  Meperidine for patients expected to have poor tolerance to esophagogastroduodenoscopy: A double-blind, randomized, controlled study.

Authors:  Chih-Wei Tseng; Malcolm Koo; Kuo-Chih Tseng; Yu-Hsi Hsieh
Journal:  United European Gastroenterol J       Date:  2018-08-24       Impact factor: 4.623

Review 9.  Pre-procedural Preparation and Sedation for Gastrointestinal Endoscopy in Patients with Advanced Liver Disease.

Authors:  Brian M Fung; Deanna J Leon; Lauren N Beck; James H Tabibian
Journal:  Dig Dis Sci       Date:  2021-06-24       Impact factor: 3.487

10.  Evaluating the content validity of two versions of an instrument used in measuring pediatric pain knowledge and attitudes in the Ghanaian context.

Authors:  Abigail Kusi Amponsah; Victoria Bam; Minna Stolt; Joonas Korhonen; Anna Axelin
Journal:  PLoS One       Date:  2020-11-06       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.